AUTHORS
Yigeng Cao II, MD, PhD, Rongli Zhang2, Donglin Yang3, Yi He, MD4, Aimin Pang5, Erlie Jiang, MD6
AFFILIATIONS
1 Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, Tianjin, China
2 Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, Tianjin, China
3 Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, Tianjin, China
4 Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, Tianjin, China
5 Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, Tianjin, China
6 Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, Tianjin, China
ABSTRACT
Abstract
Background
Secondary poor graft function (sPGF) is a life-threatening complication following allogeneic hematopoietic stem cell transplantation (allo-HSCT), characterized by persistent cytopenias despite complete donor chimerism. Currently, no standardized treatment is available for sPGF.
Umbilical cord blood mononuclear cells (UCB-MNCs) are heterogeneous, comprising hematopoietic stem cells, immune regulatory cells, and other functional subsets. These cells have been shown to secrete hematopoietic growth factors, promote tissue repair, and modulate the immune microenvironment, suggesting potential for restoring hematopoiesis in sPGF.
Aims
To conduct a prospective clinical study to evaluate the safety and optimal dosage of UCB-MNCs in the treatment of sPGF.
Methods
We conducted an open-label, phase 1 clinical trial (ClinicalTrials.gov, NCT06792682) using a 3+3 dose-escalation design to assess safety and preliminary efficacy.
Eligible patients were ≥18 years of age, met the diagnostic criteria for sPGF, and had an Eastern Cooperative Oncology Group (ECOG) performance status ≤2.
In the dose-escalation phase, patients were sequentially enrolled into three cohorts receiving UCB-MNCs at doses of 2.0×106, 3.5×106, and 5.0×106 cells/kg per infusion. All patients received four consecutive weekly intravenous infusions with standard supportive care.
The primary endpoint was safety, assessed by the incidence and severity of adverse events (AEs), graded according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Secondary exploratory efficacy endpoints included time to neutrophil and platelet recovery.
Results
As of August 1, 2026, nine patients (three each in the 2.0×106 cells/kg, 3.5×106 cells/kg, and 5.0×106 cells/kg cohorts) had completed the four-week UCB-MNCs infusion protocol and a minimum follow-up of six weeks.
During treatment and follow-up, three patients (33.3%) experienced notable adverse events, including one case of CMV viremia (CTCAE grade 2), one case of pulmonary infection (parainfluenza virus, CTCAE grade 1), and one case of cGVHD (CTCAE grade 2). All adverse events occurred in the medium-dose group and were successfully managed with standard clinical interventions; all events resolved or were controlled. None of the reported AEs were considered related to UCB-MNCs infusion.
No dose-limiting toxicities (DLTs) were observed in any cohort. Notably, no intravenous UCB-MNCs infusion-related adverse events—such as fever, chills, hypotension, or allergic reactions—occurred during or within 24 hours after administration. Throughout the study period, all patients maintained stable vital signs and organ function, with no deaths reported at the last follow-up.
In terms of therapeutic response, all three patients in the high-dose group (5×106 cells/kg) exhibited platelet counts that remained stably above the threshold of 20×10?/L starting from week 1, week 4, and week 5 post-treatment, respectively; in contrast, platelet counts in most patients of the other two groups continued to fluctuate around the threshold. Furthermore, all three patients in the high-dose group achieved hemoglobin levels that were stably maintained above the threshold of 80 g/L beginning at week 2, week 7, and week 7 post-treatment, respectively, whereas hemoglobin levels in most patients of the other groups had not yet reached this threshold. Based on these findings, we cautiously postulate that cell infusion using the dose and dosing interval of the high-dose group may facilitate accelerated hematologic recovery in patients with sPGF.
Conclusions
This phase 1 dose-escalation study indicates that repeated intravenous infusions of UCB-MNCs at doses of 2.0×106 cells/kg, 3.5×106 cells/kg, and 5.0×106 cells/kg are well tolerated in sPGF patients. The high-dose level may facilitate accelerated hematologic recovery in patients with sPGF.
DISCLOSURES
Yigeng Cao II, MD, PhD: No relevant conflicts of interest to declare.